Credit Suisse remains bullish on Regeneron Credit Suisse remains bullish on Regeneron given Eylea long-term growth prospects, the late stage piprline, and top-line growth. The firm reiterates its Outperform rating and $340 price target.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Regeneron expected to receive priority review at Piper Jaffray Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
Regeneron price target raised to $436 from $389 at Leerink Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.